Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 17

1.

The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer.

Mvundura M, Grosse SD, Hampel H, Palomaki GE.

Genet Med. 2010 Feb;12(2):93-104. doi: 10.1097/GIM.0b013e3181cd666c.

PMID:
20084010
2.

Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation.

Patrick AR, Avorn J, Choudhry NK.

Circ Cardiovasc Qual Outcomes. 2009 Sep;2(5):429-36. doi: 10.1161/CIRCOUTCOMES.108.808592.

3.

A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing.

Meckley LM, Gudgeon JM, Anderson JL, Williams MS, Veenstra DL.

Pharmacoeconomics. 2010;28(1):61-74. doi: 10.2165/11318240-000000000-00000.

PMID:
20014877
4.

Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin.

Kangelaris KN, Bent S, Nussbaum RL, Garcia DA, Tice JA.

J Gen Intern Med. 2009 May;24(5):656-64. doi: 10.1007/s11606-009-0949-1. Review. Erratum in: J Gen Intern Med. 2009 Dec;24(12):1358.

5.

Estimation of the warfarin dose with clinical and pharmacogenetic data.

International Warfarin Pharmacogenetics Consortium., Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA.

N Engl J Med. 2009 Feb 19;360(8):753-64. doi: 10.1056/NEJMoa0809329. Erratum in: N Engl J Med. 2009 Oct 15;361(16):1613. Dosage error in article text.

6.

Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation.

Eckman MH, Rosand J, Greenberg SM, Gage BF.

Ann Intern Med. 2009 Jan 20;150(2):73-83.

PMID:
19153410
7.

Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives.

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group..

Genet Med. 2009 Jan;11(1):35-41. doi: 10.1097/GIM.0b013e31818fa2ff.

8.

Feasibility of screening for Lynch syndrome among patients with colorectal cancer.

Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Clendenning M, Sotamaa K, Prior T, Westman JA, Panescu J, Fix D, Lockman J, LaJeunesse J, Comeras I, de la Chapelle A.

J Clin Oncol. 2008 Dec 10;26(35):5783-8. doi: 10.1200/JCO.2008.17.5950.

9.

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G; American College of Chest Physicians..

Chest. 2008 Jun;133(6 Suppl):160S-198S. doi: 10.1378/chest.08-0670.

PMID:
18574265
10.

Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin.

Flockhart DA, O'Kane D, Williams MS, Watson MS, Flockhart DA, Gage B, Gandolfi R, King R, Lyon E, Nussbaum R, O'Kane D, Schulman K, Veenstra D, Williams MS, Watson MS; ACMG Working Group on Pharmacogenetic Testing of CYP2C9, VKORC1 Alleles for Warfarin Use..

Genet Med. 2008 Feb;10(2):139-50. doi: 10.1097/GIM.0b013e318163c35f.

PMID:
18281922
11.

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.

Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, Kahn SF, May HT, Samuelson KM, Muhlestein JB, Carlquist JF; Couma-Gen Investigators..

Circulation. 2007 Nov 27;116(22):2563-70.

12.

Warfarin pharmacogenetics: economic considerations.

Hughes DA, Pirmohamed M.

Pharmacoeconomics. 2007;25(11):899-902. No abstract available.

PMID:
17960949
13.
14.

Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin.

Limdi NA, McGwin G, Goldstein JA, Beasley TM, Arnett DK, Adler BK, Baird MF, Acton RT.

Clin Pharmacol Ther. 2008 Feb;83(2):312-21.

15.

The cost-effectiveness of warfarin pharmacogenomics.

Veenstra DL.

J Thromb Haemost. 2007 Sep;5(9):1974-5. No abstract available.

16.

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.

Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE.

N Engl J Med. 2005 Jun 2;352(22):2285-93.

17.

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.

Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE.

JAMA. 2002 Apr 3;287(13):1690-8.

PMID:
11926893

Supplemental Content

Support Center